- Home
- EBON vs RNTX Comparison
EBON vs RNTX Comparison
Compare EBON & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBON
- RNTX
- Stock Information
- Founded
- EBON 2010
- RNTX 2001
- Country
- EBON China
- RNTX United States
- Employees
- EBON N/A
- RNTX N/A
- Industry
- EBON Semiconductors
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- EBON Technology
- RNTX Health Care
- Exchange
- EBON Nasdaq
- RNTX Nasdaq
- Market Cap
- EBON 24.4M
- RNTX 28.0M
- IPO Year
- EBON 2020
- RNTX N/A
- Fundamental
- Price
- EBON $4.95
- RNTX $1.12
- Analyst Decision
- EBON
- RNTX Hold
- Analyst Count
- EBON 0
- RNTX 1
- Target Price
- EBON N/A
- RNTX N/A
- AVG Volume (30 Days)
- EBON 10.5K
- RNTX 128.0K
- Earning Date
- EBON 08-15-2025
- RNTX 11-13-2025
- Dividend Yield
- EBON N/A
- RNTX N/A
- EPS Growth
- EBON N/A
- RNTX N/A
- EPS
- EBON N/A
- RNTX N/A
- Revenue
- EBON $7,337,066.00
- RNTX N/A
- Revenue This Year
- EBON N/A
- RNTX N/A
- Revenue Next Year
- EBON N/A
- RNTX N/A
- P/E Ratio
- EBON N/A
- RNTX N/A
- Revenue Growth
- EBON 104.28
- RNTX N/A
- 52 Week Low
- EBON $3.00
- RNTX $1.04
- 52 Week High
- EBON $10.94
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- EBON 69.71
- RNTX 43.50
- Support Level
- EBON $4.01
- RNTX $1.07
- Resistance Level
- EBON $4.20
- RNTX $1.43
- Average True Range (ATR)
- EBON 0.32
- RNTX 0.13
- MACD
- EBON 0.09
- RNTX -0.01
- Stochastic Oscillator
- EBON 92.19
- RNTX 13.03
About EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.